Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)

Intravenous immunoglobulin (IVIg) is one of the first‐line therapies for inflammatory neuropathies. Clinical use of IVIg for these disorders is limited by expense and availability. Here, we investigated a synthetic product alternative to IVIg. The aim of this study was to test the therapeutic efficacy of a novel recombinant polyvalent murine IgG2a Fc compound (stradomer™) in experimental autoimmune neuritis (EAN). Seventy‐four Lewis rats were immunized with myelin, randomized into three groups, and were treated with albumin, IVIg, or stradomer at 1% of IVIg dose. Rats were assessed clinically, electrophysiologically, and histologically. The clinical disease severity was evaluated by clinical grading and weight changes. The electrophysiological studies recorded motor conduction velocity (MCV), amplitudes, and latencies of the evoked compound muscle action potential (CMAP) and spinal somatosensory evoked potential. The treatment efficacy of the IVIg and stradomer groups was compared to the albumin (control) group. We demonstrate that stradomer has a similar therapeutic efficacy to human IVIg in EAN. Rats receiving stradomer or IVIg showed significantly lower clinical scores and less prominent weight loss compared with controls. A statistically significant improvement in both MCV and the amplitudes of distal and proximal evoked CMAP was observed in the stradomer and IVIg groups. Finally, treatment with both IVIg and stradomer resulted in statistically less inflammation and demyelinating changes in the sciatic nerve as evidenced by lower histological grade. These results reveal the potential of using fully recombinant multimerized immunoglobulin Fc instead of IVIg for treating inflammatory neuropathies.

[1]  W. Norton,et al.  MYELINATION IN RAT BRAIN: METHOD OF MYELIN ISOLATION 1 , 1973, Journal of neurochemistry.

[2]  C. Tempelis,et al.  The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression. , 1978, Journal of immunology.

[3]  Lumbar-spinal somatosensory evoked potentials in the rat after stimulation of the tibial nerve , 1985, Experimental Neurology.

[4]  K. Toyka,et al.  The role of macrophages in experimental autoimmune neuritis induced by a P2‐Specific T‐Cell line , 1988, Annals of neurology.

[5]  H. Ziltener,et al.  Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. , 1990, Cellular immunology.

[6]  J. Pollard,et al.  Patterns of conduction impairment in experimental allergic neuritis. An electrophysiological and histological study. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[7]  J. Pollard,et al.  Synergy between antibody and P2-reactive T cells in experimental allergic neuritis , 1995, Journal of Neuroimmunology.

[8]  T. Bertorini,et al.  Complications of intravenous gammaglobulin in neuromuscular and other diseases , 1996, Muscle & nerve.

[9]  R. Gold,et al.  Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat , 1997, Journal of Neuroimmunology.

[10]  N. Yuki,et al.  Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis , 1997, Journal of Neuroimmunology.

[11]  R. Hughes,et al.  Human immunoglobulin ameliorates rat experimental autoimmune neuritis. , 1997, Brain : a journal of neurology.

[12]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[13]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[14]  C. Hack,et al.  Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. , 2001, Blood.

[15]  W. Sewell,et al.  Immunomodulatory action of intravenous immunoglobulin , 2002, Immunology.

[16]  R. Gold,et al.  Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models , 2002, Neuromuscular Disorders.

[17]  M. Dalakas,et al.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, Pharmacology & therapeutics.

[18]  R. Lemieux,et al.  Tetramolecular immune complexes are more efficient than IVIg to prevent antibody‐dependent in vitro and in vivo phagocytosis of blood cells , 2004, British journal of haematology.

[19]  G. Brittinger,et al.  Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? , 1985, Blut.

[20]  J. Freedman,et al.  Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? , 2005, The Journal of clinical investigation.

[21]  S. Lacroix-Desmazes,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin , 2005, Clinical and Experimental Medicine.

[22]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[23]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[24]  A. Lazarus,et al.  Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia , 2006, Pediatric blood & cancer.

[25]  M. Madaio,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[26]  S. Kaveri,et al.  Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[27]  J. Ravetch,et al.  The antiinflammatory activity of IgG: the intravenous IgG paradox , 2007, The Journal of experimental medicine.

[28]  R. Clynes.  Protective mechanisms of IVIG. , 2007, Current opinion in immunology.

[29]  Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of Experimental Medicine.

[30]  R. Steinman,et al.  Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program , 2007, The Journal of experimental medicine.

[31]  J. Pollard,et al.  Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin , 2007, Journal of Neuroimmunology.

[32]  J. Balthasar,et al.  Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. , 2007, Blood.

[33]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[34]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.

[35]  S. Jacob,et al.  Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies , 2009, Current neuropharmacology.

[36]  F. Marincola,et al.  Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science. , 2009, Immunotherapy.

[37]  W. Oertel,et al.  Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy , 2009, Proceedings of the National Academy of Sciences.

[38]  M. Jansen,et al.  IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN , 2010, Journal of Neuroimmunology.

[39]  J. Dubost,et al.  Treatment of inflammatory muscle disease in adults. , 2010, Joint, bone, spine : revue du rhumatisme.

[40]  S. D'Amore,et al.  Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake , 2011, Clinical and Experimental Medicine.

[41]  J. Lünemann,et al.  Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy , 2010, Journal of Clinical Immunology.

[42]  E. Nobile‐Orazio,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. , 2010, Current opinion in neurology.

[43]  J. Pollard,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.

[44]  E. Hazard,et al.  Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome , 2011, BMC health services research.

[45]  N. Yuki,et al.  The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action , 2011, Expert opinion on pharmacotherapy.

[46]  E. Cantin,et al.  Passively Administered Pooled Human Immunoglobulins Exert IL-10 Dependent Anti-Inflammatory Effects that Protect against Fatal HSV Encephalitis , 2011, PLoS pathogens.

[47]  J. Lünemann,et al.  Expression and function of the inhibitory Fcγ‐receptor in CIDP , 2011, Journal of the peripheral nervous system : JPNS.

[48]  B. Crestani,et al.  IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. , 2012, Blood.

[49]  J. Köhl,et al.  The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. , 2012, Immunobiology.

[50]  J. Bystryn,et al.  Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update , 2012, Autoimmunity.

[51]  H. Olsen,et al.  Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice , 2012, Arthritis Research & Therapy.